JACKSONVILLE, Fla., May 7, 2018 /PRNewswire/ -- TapImmune Inc. (NASDAQ: TPIV), a leading clinical-stage immuno-oncology company
with ongoing clinical trials in ovarian and breast cancer, today announced that its President and CEO, Peter Hoang, will give a company presentation at the 2018 NYC Oncology Investor Conference, held May 8-9, 2018 at Wilson Sonsini Goodrich & Rosati in New York City.
Presentation Details
Date: Wednesday, May 9 th, 2018
Time: 3:00 PM ET
About TapImmune Inc.
TapImmune Inc. is a leader in the development of novel immunotherapies for cancer, with multiple Phase 2 and Phase 1b/2 clinical studies currently ongoing for the treatment of ovarian and breast cancer. The company's peptide
or nucleic acid-based immunotherapeutic products comprise multiple naturally processed epitopes (NPEs) that are designed to
comprehensively stimulate a patient's killer T-cells and helper T-cells, and to restore or further augment antigen presentation
using proprietary nucleic acid-based expression systems. This unique approach can produce off-the-shelf T-cell vaccine candidates
that elicit a broad-based T-cell response and can be used without respect to HLA type. The company's technologies may be used as
stand-alone medications or in combination with other treatment modalities.
For additional information, please visit: https://tapimmune.com/
To receive future press releases via email, please visit:
https://tapimmune.com/investors/email-alerts/
Follow us on Twitter @Tapimmune_Inc, or follow
us on Facebook.
For answers to frequently asked questions, please visit our FAQs page:
https://tapimmune.com/investors/frequently-asked-questions/
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995.
Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any
other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters,
are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other
factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and
factors include, but are not limited to the results of the Phase 2 clinical trials, the ability to obtain regulatory approval of
TPIV200, the Company's ability to raise future financing for continued development and the ability to successfully commercialize
TPIV200 as well as the risks and uncertainties set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which
are available through EDGAR at www.sec.gov. The Company assumes no obligation to
update the forward-looking statements.
View original content with multimedia:http://www.prnewswire.com/news-releases/tapimmune-to-present-at-2018-nyc-oncology-investor-conference-300643089.html
SOURCE TapImmune Inc.